Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 102

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 102
---
 The patent pending applications for our product candidates are expected to expire on various dates. Upon the expiration, we will not be able to assert such licensed patent rights against potential competitors, which would materially adversely affect our business, financial condition, results of operations and prospects. Risks Related to Ownership of our Securities Sales of a substantial number of our securities in the public market by our existing securityholders could cause the price of our Common Stock and Warrants to fall. The securities being offered in this prospectus represent a substantial percentage of our outstanding shares of Common Stock and Warrants. Sales of a substantial number of shares of our Common Stock in the public market could occur at any time (after the expiration of any applicable lock-up period, assuming the satisfaction of any applicable vesting conditions and subject to the beneficial ownership and stock exchange limitations described herein). These sales, or the perception in the market that the holders of a large number of shares of our Common Stock intend to sell shares, could increase the volatility of the market price of our Common Stock or result in a significant decline in the public trading price of our Common Stock. 55 The resale, or expected or potential resale, of a substantial number of shares of our Common Stock in the public market could adversely affect the market price for our Common Stock and make it more difficult for you to sell your holdings at times and prices that you determine are appropriate. Accordingly, the adverse market and price pressures resulting from an offering pursuant to the registration statement may continue for an extended period of time. Sales of substantial number of such shares in the public market could adversely affect the market price of our Common Stock. In addition to this prospectus, we have filed (in each case, the share number set forth below has been adjusted for the Reverse Stock Split):

| ● | a registration                                                                                                                    
 statement with the SEC for purposes of registering the resale from time to time of up to 2,100,000 Shares of Common Stock, which  
 consists of (i) 2,086,357 shares of Common Stock under the New Keystone Purchase Agreement and (ii) 13,643 shares of Common Stock 
 under the Old Keystone Purchase Agreement;                                                                                        |

| ● | a registration statement                                                                                                         
 with the SEC for purposes of registering the resale from time to time of up to 266,191 Shares of Common Stock, which consists of 
 (i) 250,000 Keystone Purchase Shares, (ii) 6,191 Keystone Commitment Shares, and (iii) 10,000 Arena Commitment Shares;